Neuroendocrine Tumor Clinical Trial
Official title:
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors (DUET-1)
This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily assess anti-tumor activity of XmAb18087 in subjects with advanced NET or GIST. The study will enroll dosing cohorts to establish a MTD/RD and regimen in subjects with advanced NET or GIST, then enroll additional subjects into separate NET and GIST expansion cohorts to collect additional data on safety and potential efficacy of XmAb18087.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04837885 -
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
|
Phase 2 | |
Completed |
NCT00789841 -
Gastrointestinal Motility in Patients With Neuroendocrine Tumors
|
N/A | |
Recruiting |
NCT05069220 -
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
|
Early Phase 1 | |
Completed |
NCT05816720 -
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
|
||
Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT01849523 -
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study
|
N/A | |
Recruiting |
NCT01448083 -
Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours
|
N/A | |
Completed |
NCT00804336 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02092714 -
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
|
||
Terminated |
NCT04073017 -
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
|
N/A | |
Completed |
NCT00434109 -
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
|
Phase 2 | |
Completed |
NCT02481804 -
Optimal Feeding for NET Patients
|
N/A | |
Completed |
NCT02472678 -
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor
|
N/A | |
Completed |
NCT02147106 -
Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study
|
||
Completed |
NCT00165230 -
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03012789 -
Surgical Intervention and the NETest
|
N/A | |
Not yet recruiting |
NCT02038738 -
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01024387 -
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Terminated |
NCT00227617 -
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
|
Phase 2/Phase 3 |